title: Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
abstract: BACKGROUND
  The prevalence, demographic features, and clinical outcomes of lung adenocarcinoma patients with novel ROS1 oncogenic rearrangement in East Asian populations are not clear. This study aimed to investigate the clinical and prognostic characteristics of lung adenocarcinoma in patients with ROS1 fusion compared with other driver mutations.
  
  
  METHODS
  Multiplex reverse transcription-polymerase chain reaction was used to detect the ROS1 fusion gene in lung adenocarcinoma cases. Immunohistochemistry was used to confirm the expression of ROS1. The demographic data and clinical outcomes of patients with the ROS1 fusion gene were compared with those of patients without the ROS1 fusion gene, including those with the EGFR mutation, EML4-ALK fusion, KRAS mutation, and quadruple-negative patients.
  
  
  RESULTS
  Of 492 patients with lung adenocarcinoma, 12 (2.4%) had the ROS1 fusion gene. Their median age was 45.0 years, significantly younger than that of the ROS1 fusion-negative cohorts (p < 0.001). Acinar (including cribriform) and solid patterns were the two most common histologic subtypes in the ROS1 fusion tumors (7 of 12, 58.3%) and were predominantly seen in CD74-ROS1 fusion tumors (66.7%). There was no significant survival difference between the ROS1 fusion-positive and ROS1 fusion-negative cohorts in surgical group, but ROS1 fusion-positive patients might have worse outcomes than EGFR-mutant patients in the stage IV group.
  
  
  CONCLUSIONS
  The ROS1 fusion gene can be successfully detected in East Asian patients with lung adenocarcinoma using multiplex reverse transcription-polymerase chain reaction. These patients tend to be younger and have characteristic histologic subtypes. Due to the small number of ROS1 fusion patients, the prognostic value of ROS1 fusion need further studies to confirm.
authors.affiliation: *Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin; †Department of Pathology; ‡Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei; §Department of Molecular Biotechnology, Da-Yeh University, Chang-Hua; ‖Department of Oncology, National Taiwan University Hospital; and ¶Graduate Institute of Oncology Cancer Research Centre, National Taiwan University, Taipei, Taiwan.
authors.forename: Yen-Fu
authors.initials: YF
authors.lastname: Chen
authors.forename: Min-Shu
authors.initials: MS
authors.lastname: Hsieh
authors.forename: Shang-Gin
authors.initials: SG
authors.lastname: Wu
authors.forename: Yih-Leong
authors.initials: YL
authors.lastname: Chang
authors.forename: Jin-Yuan
authors.initials: JY
authors.lastname: Shih
authors.forename: Yi-Nan
authors.initials: YN
authors.lastname: Liu
authors.forename: Meng-Feng
authors.initials: MF
authors.lastname: Tsai
authors.forename: Tzu-Hsiu
authors.initials: TH
authors.lastname: Tsai
authors.forename: Chong-Jen
authors.initials: CJ
authors.lastname: Yu
authors.forename: James Chih-Hsin
authors.initials: JC
authors.lastname: Yang
authors.forename: Pan-Chyr
authors.initials: PC
authors.lastname: Yang
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis / Q000235:genetics; D044466:Asian People / Q000235:genetics*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000032:analysis / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009154:Mutation; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000235:genetics*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000032:analysis / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D012737:Sex Factors; D050614:Sodium-Phosphate Cotransporter Proteins, Type IIb / Q000032:analysis / Q000235:genetics; D015996:Survival Rate; D053671:Syndecan-4 / Q000032:analysis / Q000235:genetics; D013624:Taiwan; D018631:ras Proteins / Q000235:genetics
chemical_list: D000944:Antigens, Differentiation, B-Lymphocyte; C522504:EML4-ALK fusion protein, human; D000949:Histocompatibility Antigens Class II; C117307:KRAS protein, human; D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; C508304:SDC4 protein, human; C493557:SLC34A2 protein, human; D050614:Sodium-Phosphate Cotransporter Proteins, Type IIb; D053671:Syndecan-4; C045084:invariant chain; C512478:EGFR protein, human; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins